SCHEMBL2391854

SCHEMBL2391854

NC(=O)Cc1ccccc1-c1ccccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
MAOB P27338 1/20 0.41
PARP15 Q460N3 1/20 0.41
PARP14 Q460N5 1/20 0.41
PARP10 Q53GL7 1/20 0.41
CXCL8 P10145 2/20 0.40
ATR Q13535 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39
PPIA P62937 2/20 0.39
MAPK8 P45983 1/20 0.39
SLC9A1 P19634 2/20 0.39
NPC1 O15118 1/20 0.38
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
SCN3A Q9NY46 1/20 0.38
GRM2 Q14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395880 0.88 ALDH1A1 (0.41) ALDH1A1MAPTL3MBTL1RAB9ALMNA
SCHEMBL2395681 0.85 PDCD1 (0.41) ALDH1A1MAPTL3MBTL1RAB9ALMNA
SCHEMBL2393136 0.85 SLC9A1 (0.42) MAPTSLC9A1
SCHEMBL2395132 0.85 ICMT (0.39) ALDH1A1MAPTL3MBTL1MAPK8SLC9A1
SCHEMBL2395238 0.85 ICMT (0.39) ALDH1A1MAPTL3MBTL1MAPK8SLC9A1
SCHEMBL9890790 0.85 PKM (0.40) ALDH1A1MAPTRAB9ALMNAMAPK8
SCHEMBL9890785 0.84 ALDH1A1 (0.41) ALDH1A1MAPTL3MBTL1RAB9ALMNA
SCHEMBL9890738 0.84 ALDH1A1 (0.41) ALDH1A1MAPTRAB9ALMNAMAOB
SCHEMBL29639794 0.84 ALDH1A1 (0.55) ALDH1A1RAB9ALMNAMAOBPARP15
SCHEMBL1031721 0.84 ALDH1A1 (0.55) ALDH1A1RAB9ALMNAMAOBPARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
WO-2010055911-A1 BIPHENYLACETAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885MAPT 3986/4885L3MBTL1 1168/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885MAPT 3986/4885L3MBTL1 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.